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Abstract Hypertension is a progressive cardiovascular
syndrome that arises from many differing, but interrelated,
etiologies. Hypertension is the most prevalent cardiovascu-
lar disorder, affecting 20% to 50% of the adult population
in developed countries. Arterial hypertension is a major risk
factor for cardiovascular diseases and death. Epidemiologic
data have shown that control of hypertension is achieved in
only a small percentage of hypertensive patients. Findings
from the World Health Organization project Monitoring
Trends and Determinants in Cardiovascular Diseases
(MONICA) showed a remarkably high prevalence (about
65%) of hypertension in Eastern Europeans. There is
virtually no difference however, between the success rate
in controlling hypertension when comparing Eastern and
Western European populations. Diagnosing hypertension
depends on both population awareness of the dangers of
hypertension and medical interventions aimed at the
detecting elevated blood pressure, even in asymptomatic
patients. Medical compliance with guidelines for the
treatment of hypertension is variable throughout Eastern
Europe. Prevalence of hypertension increases with age, and
the management of hypertension in elderly is a significant
problem. The treatment of hypertension demands a compre-
hensive approach to the patient with regard to cardiovascular
risk and individualization of hypertensive therapy.
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Introduction
Hypertension is a progressive cardiovascular disease that
arises from many differing but inter-related etiologies [1].
Early markers of the syndrome are often present before
there is a sustained rise in blood pressure (BP) elevation.
Hypertension therefore, cannot be classified solely using
discrete BP parameters [1, 2]. Progression of the syndrome
is strongly associated with functional and structural cardiac
and vascular abnormalities that damage the heart, kidneys,
brain, vasculature, and other organs, which in turn leads to
premature morbidity and death [1]. Hypertension is the
most prevalent cardiovascular (CV) disorder in developed
countries and affects 20% to 50% of the adult population
[2].
The European Society of Hypertension/European
Society of Cardiology (ESH/ESC) guidelines [3]a n dt h e
World Health Organization–International Society of Hy-
pertension (WHO/ISH) guidelines [4] suggested that BP
control can be described as adequate when systolic and
diastolic BPs of <140 mm Hg and <90 mm Hg, respectively,
are achieved.
Furthermore the Joint National Committee (JNC) 7 and
European Society of Hypertension/European Society of
Cardiology (ESH/ESC) guidelines [3, 5] have suggested that
systolic and diastolic BP values of <130 mm Hg and <80
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DOI 10.1007/s12170-010-0152-2mm Hg, respectively, should be the target range for special
populations such as those affected by diabetes or renal
disease. However, the current recommendations of the ESH
(2009) indicate that we do not have enough data to
demonstrate that a decreased in BP below 130/80 mm Hg
is connected with the reduction of cardiovascular events.
Moreover, intensive BP lowering might increase CV events
(the J-curve phenomenon) [6￿].
Epidemiologic data have revealed that the BP control is
achieved in only a small percentage of hypertensive
patients [6￿, 7, 8]. In central European countries, BP control
is only 20% to 25%.
Many studies have demonstrated that elevated BP is a
risk factor for coronary heart disease, heart failure, stroke,
peripheral arterial disease, and renal failure in both men and
women (Fig. 1)[ 9–13].
There is evidence that raised BP inversely correlates with
cognitive function and that hypertension is associated with an
increased incidence of dementia [14]. Data from studies
involving 1 million patients have indicated that death from
both CHD and stroke increases progressively and linearly
from BP levels as low as 115 mm Hg systolic and 75 mm Hg
diastolic [15]. Increased risks are present in all age groups,
ranging from 40 to 89 years old. For every 20-mm Hg
systolic or 10-mm Hg diastolic increase in BP, there is a
doubling of mortality from both CHD and stroke. In
addition, longitudinal data obtained from the Framingham
Heart Study have indicated that BP values in the 130–139/
85–89 mm Hg range are associated with a more than twofold
increase in relative risk from cardiovascular disease com-
pared with those with BP levels below 120/80 mm Hg [16].
A large number of randomized trials have confirmed that
the main benefits of antihypertensive therapy are the result
of BP lowering per se, independent of the class of drug
used to lower blood pressure [17].
The odds ratio or the relative risk of CVD to the individual
increases with the severity of hypertension, although the
attributable risk is greatest for mild hypertension due to its
greater prevalence in the general population. Therefore, the
burden of CVD arising from hypertension in the general
population comes from those with relatively mild BP
elevation [18].
Compared to normotensive individuals, those with an
elevated BP have an increased tendency to have other risk
factors for CVD (ie, diabetes, insulin resistance, dyslipide-
mia) [19, 20], together with various types and degrees of
target organ damage. Because risk factors may interact
positively with each other, the total CV risk of hypertensive
patients is frequently high when BP elevation is only mild
or moderate [21].
The Prevalence and Awareness of Hypertension
When comparing the prevalence of hypertension, one
should be aware that this is heavily dependent on the
definition of hypertension, the nature of the population
being studied, the number of BP readings taken on each
occasion and, finally, on the number of visits to the doctor
[22￿]. The prevalence of hypertension reported by Kearney
et al. [23] varies widely, with rates as low as 3.4% in rural
Indian men and as high as 72.5% in Polish women.
Subregions with populations where consistently high mean
systolic BP levels have been detected include parts of
Eastern Europe and Africa. A comparative analysis of
hypertension in North Americans aged 35 to 64 years
showed a 60% lower prevalence of hypertension compared
to similar subjects in European countries [23]. The
difference in prevalence could not be explained by differ-
ences in body mass index (North America 27.1 kg/m
2,
Europe 26.9 kg/m
2). Findings from the WHO project
Monitoring Trends and Determinants in Cardiovascular
Diseases (MONICA) Project showed a remarkably higher
prevalence of hypertension in Eastern Europe (about 65%),
but virtually no difference in the rates of controlled
hypertension among Eastern and Western populations [24,
25]. Epidemiologic studies (NATPOL III Plus) indicate that
the prevalence of hypertension in Polish population is 67%.
Of all patients with hypertension in Poland, only 12% are
successfully treated (Table 1)[ 26].
The data from the Polish multicenter, nationwide project
WOBASZ assessed 13,545 subjects (6392 men and 7153
women) in the years 2003 to 2005 and showed that the
average incidence of hypertension in Poland was about
36% [27]. Hypertension was more commonly detected in
men (42.1%) compared to women (32.9%). This sex
difference did depend, however, on the age at which the
hypertension was detected [27]. The percentage of patients
with controlled BP was low (10% in men and 16% in
women). This confirms the observations from the NATPOL
Fig. 1 Elevated blood pressure is a risk factor for many cardiovas-
cular diseases. CAD coronary artery disease, CHF congestive heart
failure, LVH left ventricular hypertrophy, PVD peripheral vascular
disease
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treated hypertensive patients was only 12% [26].
In Russia, 97.1% of the hypertensive population was
above the recommended target level (<140/90 mm Hg) at
their first visit to an outpatient department. BP control was
poorer in patients with a BP target of <130/80 mm Hg
(20.1%) than in those with a higher target BP (25.9%) [28].
Detecting hypertension depends on both the awareness
of population and the intervention of medical staff and
should be aimed at the recording of elevated BP, even in
symptomless patients. In the Czech Republic, there was an
increase in the awareness of the dangers of hypertension
(from 49.5% to 67.2%) and the treatment of hypertension
(from 29.3% to 49.3%) from 1985 to 2001 [29]. Regional
differences in BP levels have been observed in a number of
developed countries. Differences were reported between
urban and rural populations, with a tendency toward higher
BP levels in urban areas.
What Influences Compliance with Antihypertensive
Therapy in Eastern Europe?
The compliance of medical staff in following antihypertension
treatment guidelines is variable. A study conducted on a
random sample of Polish primary care doctors working in
clinics contracted by the National Health Insurance Funds
aimed to assess whether the doctors were following particular
drug regimen guidelines. Doctors completed a questionnaire
consisting of eight case vignettes describing patients with
elevated BP [30￿]. The cases differed on three variables
related to the level of blood pressure, the presence or absence
of diabetes mellitus, and the presence or absence of other risk
factors. Doctors were asked to give their treatment decision in
each case. One hundred twenty-five doctors (65% response
rate) completed the questionnaire. Compliance with treatment
guidelines was judged to be 51%. Poor compliance with
guidelines was noted for patients with diabetes mellitus. The
level of blood pressure was the strongest predictor of drug
treatment. Angiotensin-converting enzyme (ACE) inhibitors
were the most frequently prescribed medications. Appropriate
decisions were more commonly associated with medical
practices in large cities [30￿].
Insufficient use of diuretics in combination antihyperten-
sive therapy is a main cause of poor BP control in Russia. The
objective of the Russian ARGUS-2 [31￿] study was to
demonstrate that a rational use of a thiazide-like diuretic,
indapamide sustained release (SR), alone or in combination,
improved BP control in patients with difficult-to-control
hypertension. The open-label, non-comparative 3-month
study without preliminary washout included 1438 hyper-
tensive patients (mean age 57.3±10.7 years, mean BP
158.8±14.2/93.4±10.0 mm Hg), with difficult-to-control
arterial hypertension who had never been treated with
diuretics. Throughoutthestudy, patientsreceivedindapamide
SR 1.5 mg daily. BP control was defined as <140/90 mm Hg
for all patients and <130/80 mm Hg for those with diabetes
mellitus or chronic nephropathy [31￿]. Approximately 75.7%
of patients also were prescribed an ACE inhibitor or an
angiotensin II receptors blocker, 43.9% a calcium channel
blocker, and 32.8% a β-blocker. The study demonstrated the
value of including the thiazide-like diuretic indapamide SR in
a combined antihypertensive regimen to control BP in
hypertensive patients with added cardiovascular risk factors
whose hypertension is difficult to treat. In 3 months after
indapamide SR administration, average BP level decreased to
131.8±9.7/80.5±6.9 mmHg, and 84.5% of the study popu-
lation achieved BP control. BP was controlled in 91.9% of
patients with isolated systolic hypertension (n=477), 74.8%
of those with diabetes (n=214), 75.6% of those with chronic
nephropathy (n=82), and 85.1% of patients with metabolic
syndrome (n=745) [31￿].
In Russia, achieving a BP target was associated with
combination therapy, a higher rate of diuretic administra-
tion, and more frequent visits to the physician [28]. During
hospitalization, a target BP of <140/< 90 mm Hg was
achieved in 87.1% of patients, and <130/< 80 mm Hg in
76.2% of patients. Low adherence to antihypertensive
treatment, lack of patient knowledge about the risks related
to hypertension, and financial problems were identified as
the main barriers to improve control of BP. Patients
considered financial issues related to antihypertensive
treatment as being much less important compared to their
physicians [28].
Bajraktari et al. [32] assessed the quality of the manage-
ment of hypertension in patients hospitalized in the
cardiology service in Kosovo. They studied patients who
were mainly referred from general practitioners, internists,
and cardiologists for a better treatment of hypertension or
because hypertension was associated with other co-
morbidities needing hospitalization. This retrospective study
included 938 consecutive hypertensive patients (63.1±11.3
years, 55.1% women). Angiotensin-converting enzyme
inhibitors (ACEI) and/or angiotensin II receptor blockers
Table 1 The effectiveness of diagnosis and treatment among adults
Poles with hypertension in NATPOL III PLUS
Hypertension Women Men Generally
Not detected 27% 40% 33%
Detected, not treated 8% 13% 10%
Treated unsuccessfully 51% 37% 45%
Treated successfully 14% 10% 12%
(Adapted from Zdrojewski et al. [26])
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group (83%). β-blockers (BB) were the second group of the
drugs that were prescribed (71%), followed by diuretics
(60%), and calcium channel blockers (26%). The most
frequent drug combination used was ACEI, BB, and diuretic
(30.5%).Adequatesystolicanddiastolicbloodpressures were
achieved in 50% of patients. Multivariate analysis identified
diabetes, (odds ratio [OR]=0.479; 95% CI, 0.339–0.677;
P<0.001), creatinine level (OR=0.997; 95% CI, 0.996–
0.999; P=0.001), and combination therapy (OR=0.445; 95%
CI, 0.253–0.774; P=0.046) as independent correlates of
in-hospital poor BP control [32].
It has been demonstrated that the optimal BP control was
far better during in-hospital treatment of hypertensive
patients than in those treated in primary health care units
[32–35]. Moreover, the behavior of physicians attending
hypertensive patients (including careful examination and
detailed information given on the rules of hypertension
therapy and hypertension complications) was shown to be a
factor that may influence better BP control in in-hospital
hypertension units [36, 37].
Hypertension in the Elderly
The management of hypertension in the elderly is a
significant problem in the countries of Eastern Europe.
Prevalence of hypertension increases with age, rising
steeply after the age of 50 years, and affects more than
50% of this population. In adulthood, systolic and
diastolic BP tends to rise with age. The increase is
somewhat greater in systolic BP, whereas diastolic BP
remains almost unaltered from age 50 years and upward.
Aging results in a progressive increase in pulse pressure,
which is the difference between systolic and diastolic
pressure [24, 38].
Guidelines for the management of hypertension include
areas where the evidence for or against treatment in certain
types patient groups is inconclusive. This is especially the
case of older patients with hypertension [3, 4].
Although a large number of randomized trials that
have included hypertensive patients aged ≥60 years have
shown that antihypertensive drugs reduce cardiovascular
morbidity and mortality, health care professionals are
often reluctant to prescribe adequate antihypertensive
therapy [39].
In a meta-analysis by the Blood Pressure Lowering
Treatment Trialists’ Collaboration (BPLTTC) [40], the
effects of different drugs in reducing BP in older and
younger adults were analyzed. The reduction in BP and the
relative risk reduction of a cardiovascular event with
various antihypertensive drugs occurred independently of
patient age. The benefits of the antihypertensive regimens
were widely comparable across age groups independent of
the drug class [40]. The BPLTTC analysis strongly
suggested that there should be early and aggressive
management of hypertension irrespective of age [40].
The Hypertension in the Very Elderly Trial (HYVET)
[41] was a double-blind, placebo-controlled trial that
included 3845 patients aged >80 years who had sustained
systolic BP ≥160 mm Hg or diastolic hypertension (90–109
mmHg). Patients were randomized to either SR indapamide
1.5 mg or placebo. In the first group, perindopril was added
as needed. Results of the HYVET study proved that early
and systematic therapy of hypertension with indapamide or
indapamide and perindopril in this age group reduces the
risk of all-cause mortality (21%), fatal and non-fatal stroke
(30%), and mortality and heart failure (64%) development.
The treatment of hypertension demands comprehensive
approach to the patient regarding global cardiovascular
risk and individualization of hypertensive therapy [41].
These studies were very important as they confirmed that
we should treat hypertension irrespective of age, but we
still do not know what should be the target BP in elderly
patients. However, it is worth noting that on the basis of
data from HYVET, in which the systolic BP was actually
lowered to 143 mm Hg, American recommendations
suggest lowering the systolic BP in persons aged 80 years
and older to 140 to 145 mm Hg if tolerated. This is
important data for Eastern Europeans countries, because
there is no current standard for optimal therapy of elderly
patients [41–44].
What is the best drug to treat hypertension in older and
younger adults? There are a few pathophysiologic mecha-
nisms that are specific in the elderly. This includes the age-
related increase in postsynaptic α-adrenoceptor–mediated
and calcium influx–dependent vasoconstriction, as well as a
decrease in plasma renin activity. The recently revised
British guidelines [42] suggested that patients younger than
55 years should be treated with ACE inhibitors and older
patients with diuretics or calcium channel blockers. On the
other hand, other European guidelines [3, 4] suggest that
evidence for an age-dependent strategy in the choice of
antihypertensive drugs is as yet insufficient. In fact, benefits
have been demonstrated in older hypertensive patients for
several drug classes such as diuretics, calcium channel
blockers, ACE inhibitors, angiotensin receptor blockers
(ARB), and BBs [43–46].
The first drug of choice in older patients often needs
to be precisely tailored to individual characteristics, as
older adults frequently have other risk factors, target
organ damage, and other associated clinical conditions.
Additionally, many patients will need two or more drugs
to control BP, since in the very old it can be particularly
difficult to obtain a systolic BP of lower than 140 mmHg
[39, 47, 48].
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Despite continuously accumulating data, many decisions on
hypertension management must still be taken without the
support of evidence from available clinical trials. The
problem with the optimal control and treatment of hyper-
tension is especially important for Central and Eastern
European countries, given the high prevalence of hyperten-
sion, but the reasons of the problems are the same as in
Western European countries and the United States. These
reasons, and obviously the problems of compliance and
therapeutic inertia are the most important reasons that
hypertension remains the most important risk factor for
cardiovascular disease and the greatest contributor to
mortality worldwide [49￿, 50￿, 51–55].
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